



January 31, 2025

Luxna Biotech Co., Ltd.

## **Notice of Reduction in Capital Reserve and Appropriation of Surplus**

Luxna Biotech Co. Ltd. (the "Company") announces that its Ordinary General Meeting of Shareholders, held on January 31, 2025, resolved to reduce capital reserve and to appropriate the surplus described below.

### **1. Purposes**

The Company will reduce its capital reserve and appropriate the surplus to make up the deficit in retained earnings carried forward and improve the Company's financial soundness.

The reduction of capital reserve satisfies the requirements of Article 449, Paragraph 1 of the Companies Act, and thus the procedures for creditors' objection will not be required.

### **2. Details of reduction in the amount of capital reserve**

(1) Amount of capital reserve reduced

744,951,000 yen

(2) Method of reducing capital reserve

The entire reduction capital reserve, 744,951,000 yen, will be transferred to other capital surplus to cover the deficit.

### **3. Details of appropriation of surplus**

Pursuant to Article 452 of the Companies Act, other capital surplus will be transferred to retained earnings brought forward to compensate for the deficit.

(1) Item and amount of surplus reduced

Other capital surplus, 744,951,000 yen

(2) Item and amount of surplus increased

Retained earnings brought forward, 744,951,000 yen

### **4. Schedule for reduction of capital reserve and appropriation of surplus**

(1) Board of Directors Resolution: January 14, 2025

(2) Date of resolution at the General Meeting of Shareholders: January 31, 2025

(3) Effective date: January 31, 2025

**【Contact】**

Luxna Biotech Co., Ltd. Management Department

E-mail: [info@luxnabiotech.co.jp](mailto:info@luxnabiotech.co.jp)

HP: <https://luxnabiotech.co.jp/>